Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                The Drug Development Process

The Drug Development Process

                        Step 1: Discovery and Development
          Step 2: Preclinical Research
          Step 3: Clinical Research
          Step 4: FDA Drug Review
          Step 5: FDA Post-Market Drug Safety Monitoring Home
          For Patients
          Learn About Drug and Device Approvals
          The Drug Development Process
          Step 3: Clinical ResearchThe Drug Development Process Step 3: Clinical Research
  
  	
    Share
    Post
    Linkedin

    Email
    PrintWhile preclinical research answers basic questions about a drug’s safety, it is not a substitute for studies of ways the drug will interact with the human body. “Clinical research” refers to studies, or trials, that are done in people. As the developers design the clinical study, they will consider what they want to accomplish for each of the different Clinical Research Phases and begin the Investigational New Drug Process (IND), a process they must go through before clinical research begins.
On this page you will find information on:
Designing Clinical Trials
  Clinical Research Phase Studies
  The Investigational New Drug Process
  Asking for FDA Assistance
  FDA IND Review Team
  Approval**Designing Clinical Trials**
Researchers design clinical trials to answer specific research questions related to a medical product. These trials follow a specific study plan, called a protocol, that is developed by the researcher or manufacturer. Before a clinical trial begins, researchers review prior information about the drug to develop research questions and objectives. Then, they decide:
Who qualifies to participate (selection criteria)
  How many people will be part of the study
  How long the study will last
  Whether there will be a control group and other ways to limit research bias
  How the drug will be given to patients and at what dosage
  What assessments will be conducted, when, and what data will be collected
  How the data will be reviewed and analyzedClinical trials follow a typical series from early, small-scale, Phase 1 studies to late-stage, large scale, Phase 3 studies.
What are the Clinical Trial Phases?
  
  Watch this video to learn about the three phases of clinical trials.
**Clinical Research Phase Studies**
Phase 1
    **Study Participants:**20 to 100 healthy volunteers or people with the disease/condition.
        **Length of Study:**Several months
        **Purpose:**Safety and dosage
            During Phase 1 studies, researchers test a new drug in normal volunteers (healthy people). In most cases, 20 to 80 healthy volunteers or people with the disease/condition participate in Phase 1. However, if a new drug is intended for use in cancer patients, researchers conduct Phase 1 studies in patients with that type of cancer.
                Phase 1 studies are closely monitored and gather information about how a drug interacts with the human body. Researchers adjust dosing schemes based on animal data to find out how much of a drug the body can tolerate and what its acute side effects are.
                As a Phase 1 trial continues, researchers answer research questions related to how it works in the body, the side effects associated with increased dosage, and early information about how effective it is to determine how best to administer the drug to limit risks and maximize possible benefits. This is important to the design of Phase 2 studies.
        
        **Approximately 70% of drugs move to the next phase**
  
  Phase 2
    ****Study Participants:****Up to several hundred people with the disease/condition.
        **Length of Study:**Several months to 2 years
        **Purpose:**Efficacy and side effects
            In Phase 2 studies, researchers administer the drug to a group of patients with the disease or condition for which the drug is being developed. Typically involving a few hundred patients, these studies aren't large enough to show whether the drug will be beneficial.
                Instead, Phase 2 studies provide researchers with additional safety data. Researchers use these data to refine research questions, develop research methods, and design new Phase 3 research protocols.
        
        **Approximately 33% of drugs move to the next phase**
  
  Phase 3
    ****Study Participants:****300 to 3,000 volunteers who have the disease or condition
        **Length of Study:**1 to 4 years
        **Purpose:**Efficacy and monitoring of adverse reactions
            Researchers design Phase 3 studies to demonstrate whether or not a product offers a treatment benefit to a specific population. Sometimes known as pivotal studies, these studies involve 300 to 3,000 participants.
                Phase 3 studies provide most of the safety data. In previous studies, it is possible that less common side effects might have gone undetected. Because these studies are larger and longer in duration, the results are more likely to show long-term or rare side effects
        
        **Approximately 25-30% of drugs move to the next phase**
  
  Phase 4
    **Study Participants:** Several thousand volunteers who have the disease/condition
        **Purpose:**Safety and efficacy
            Phase 4 trials are carried out once the drug or device has been approved by FDA during the Post-Market Safety Monitoring


Learn more about Clinical Trials.
**The Investigational New Drug Process**
Drug developers, or sponsors, must submit an Investigational New Drug (IND) application to FDA before beginning clinical research.
In the IND application, developers must include:
Animal study data and toxicity (side effects that cause great harm) data
  Manufacturing information
  Clinical protocols (study plans) for studies to be conducted
  Data from any prior human research
  Information about the investigator**Asking for FDA Assistance**
Drug developers are free to ask for help from FDA at any point in the drug development process, including:
Pre-IND application, to review FDA guidance documents and get answers to questions that may help enhance their research
  After Phase 2, to obtain guidance on the design of large Phase 3 studies
  Any time during the process, to obtain an assessment of the IND applicationEven though FDA offers extensive technical assistance, drug developers are not required to take FDA’s suggestions. As long as clinical trials are thoughtfully designed, reflect what developers know about a product, safeguard participants, and otherwise meet Federal standards, FDA allows wide latitude in clinical trial design.
**FDA IND Review Team**
The review team consists of a group of specialists in different scientific fields. Each member has different responsibilities.
***Project Manager:*** Coordinates the team’s activities throughout the review process, and is the primary contact for the sponsor.
  ***Medical Officer:*** Reviews all clinical study information and data before, during, and after the trial is complete.
  ***Statistician:***Interprets clinical trial designs and data, and works closely with the medical officer to evaluate protocols and safety and efficacy data.
  ***Pharmacologist:***Reviews preclinical studies.
  ***Pharmakineticist:***Focuses on the drug’s absorption, distribution, metabolism, and excretion processes.Interprets blood-level data at different time intervals from clinical trials, as a way to assess drug dosages and administration schedules.
  ***Chemist:***Evaluates a drug’s chemical compounds. Analyzes how a drug was made and its stability, quality control, continuity, the presence of impurities, etc.
  ***Microbiologist:***Reviews the data submitted, if the product is an antimicrobial product, to assess response across different classes of microbes.**Approval**
The FDA review team has 30 days to review the original IND submission. The process protects volunteers who participate in clinical trials from unreasonable and significant risk in clinical trials. FDA responds to IND applications in one of two ways:
Approval to begin clinical trials.
  Clinical hold to delay or stop the investigation. FDA can place a clinical hold for specific reasons, including:
    Participants are exposed to unreasonable or significant risk.
      Investigators are not qualified.
      Materials for the volunteer participants are misleading.
      The IND application does not include enough information about the trial’s risks.A clinical hold is rare; instead, FDA often provides comments intended to improve the quality of a clinical trial. In most cases, if FDA is satisfied that the trial meets Federal standards, the applicant is allowed to proceed with the proposed study.
The developer is responsible for informing the review team about new protocols, as well as serious side effects seen during the trial. This information ensures that the team can monitor the trials carefully for signs of any problems. After the trial ends, researchers must submit study reports.
This process continues until the developer decides to end clinical trials or files a marketing application. Before filing a marketing application, a developer must have adequate data from two large, controlled clinical trials.

                                                                                  Content current as of:
      01/04/2018The Drug Development Process

          
                        Step 1: Discovery and Development
          Step 2: Preclinical Research
          Step 3: Clinical Research
          Step 4: FDA Drug Review
          Step 5: FDA Post-Market Drug Safety Monitoring
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop